Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stock-based Compensation (Tables)

Stock-based Compensation (Tables)

9 Months Ended

Sep. 30, 2014

Schedule of stock-based compensation expense related to all of the entity's stock-based awards

Total stock-based compensation expense related to all of our share-based payments that we recognized for the three and nine months ended September 30, 2014 and 2013 were as follows (in thousands):

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2014		2013		2014		2013
Research and development	$	1,151	$	1,035	$	3,654	$	3,060
General and administrative	929		789		2,922		2,304
Restructuring charges	—		239		—		239
Total stock-based compensation expense	$	2,080	$	2,063	$	6,576	$	5,603

Summary of weighted-average assumptions relating to options granted pursuant to equity incentive plans

	Equity Incentive Plans				Equity Incentive Plans
	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2014		2013		2014		2013
Risk-free interest rate	2.2	%	1.5	%	2.2	%	1.0	%
Expected term (in years)	6.0		5.0		6.6		5.4
Dividend yield	0.0	%	0.0	%	0.0	%	0.0	%
Expected volatility	67.1	%	69.5	%	74.9	%	72.5	%

Summary of weighted-average assumptions used to calculate fair value of purchase rights granted under Employee Stock Purchase Plan

	Employee Stock Purchase Plan
	Nine Months Ended
	September 30,
	2014		2013
Risk-free interest rate	0.3	%	0.2	%
Expected term (in years)	1.7		1.4
Dividend yield	0.0	%	0.0	%
Expected volatility	66.0	%	64.4	%